Hepsor begins development of a business center in Rae municipality

31 minutes ago
GlobeNewswire

Hepsor AS subsidiary, Hepsor VT49 OÜ, has signed long-term lease agreements with Maxima Eesti OÜ and GYM Eesti OÜ and…

US PCE Prices Seen Up 0.1%; Yearly Rate to Decelerate

32 minutes ago

The US Personal Consumption Expenditures (PCE) price index is anticipated to increase by 0.1% month-over-month in April 2025, following a…

Australian Shares Rise Amid Weak Economic Data

32 minutes ago

The S&P/ASX 200 Index experienced a modest increase of 0.3%, closing at 8,435 on Friday, as early losses were offset…

Hungary’s Producer Price Index Sees a Slight Uptick in April

32 minutes ago

In April 2025, Hungary's Producer Price Index (PPI) experienced a modest increase, rising to 7.9% compared to the same month…

Swedish Economy Shrinks Unexpectedly

32 minutes ago

In the first quarter of 2025, Sweden's economy contracted by 0.2% on a quarterly basis, surprising analysts who had anticipated…

Lithuania Q1 GDP Growth Revised Lower

32 minutes ago

In the first quarter of 2025, Lithuania's economy experienced a modest growth of 0.4% on a quarter-on-quarter basis. This was…

ZETADISPLAY AB (publ) INTERIM REPORT 1 JANUARY – 31 MARCH 2025

2 hours ago

Q1 Interim report JANUARY – MARCH 2025 for ZetaDisplay AB (publ) is now available at ir.zetadisplay.com Report summary: Continued Growth…

EssilorLuxottica to acquire Optegra clinics, another leap forward in its med-tech strategy

2 hours ago

EssilorLuxottica to acquire Optegra clinics,another leap forward in its med-tech strategy Acquisition of leading ophthalmology platform from MidEuropa will advance…

Moody’s Affirms Bigbank’s Ratings and Assessments

2 hours ago

Moody’s Ratings (Moody’s) has affirmed all ratings and assessments of Bigbank AS, which were assigned last year. Moody's confirmed the…

Roche’s fenebrutinib maintains near-complete suppression of disease activity and disability progression for up to two years in people with relapsing multiple sclerosis

3 hours ago

Patients on fenebrutinib had low relapse rates with data showing no active brain lesions or disability progression after nearly two…

This website uses cookies.